TLV: TEVA Statistics

Total Valuation

Teva Pharmaceutical Industries has a market cap or net worth of ILS 91.39 billion. The enterprise value is 150.73 billion.

Market Cap	91.39B
Enterprise Value	150.73B

Important Dates

The next estimated earnings date is Wednesday, January 29, 2025.

Earnings Date	Jan 29, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.87%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.13B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.40, with an EV/FCF ratio of 29.64.

EV / Earnings	-42.28
EV / Sales	2.46
EV / EBITDA	8.40
EV / EBIT	11.08
EV / FCF	29.64

Financial Position

The company has a current ratio of 0.89, with a Debt / Equity ratio of 3.02.

Current Ratio	0.89
Quick Ratio	0.49
Debt / Equity	3.02
Debt / EBITDA	3.92
Debt / FCF	14.09
Interest Coverage	3.69

Financial Efficiency

Return on equity (ROE) is -17.52% and return on invested capital (ROIC) is 8.72%.

Return on Equity (ROE)	-17.52%
Return on Assets (ROA)	5.56%
Return on Capital (ROIC)	8.72%
Revenue Per Employee	1.69M
Profits Per Employee	-96,348
Employee Count	36,472
Asset Turnover	0.40
Inventory Turnover	2.10

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +103.00% in the last 52 weeks. The beta is 0.88, so Teva Pharmaceutical Industries's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	+103.00%
50-Day Moving Average	6,463.90
200-Day Moving Average	6,041.49
Relative Strength Index (RSI)	76.92
Average Volume (20 Days)	1,746,919

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.78

Income Statement

In the last 12 months, Teva Pharmaceutical Industries had revenue of ILS 62.35 billion and -3.56 billion in losses. Loss per share was -3.18.

Revenue	62.35B
Gross Profit	31.07B
Operating Income	13.87B
Pretax Income	-1.96B
Net Income	-3.56B
EBITDA	17.79B
EBIT	13.87B
Loss Per Share	-3.18

Full Income Statement

Balance Sheet

The company has 12.34 billion in cash and 71.65 billion in debt, giving a net cash position of -59.31 billion.

Cash & Cash Equivalents	12.34B
Total Debt	71.65B
Net Cash	-59.31B
Net Cash Per Share	n/a
Equity (Book Value)	23.73B
Book Value Per Share	19.90
Working Capital	-5.51B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.90 billion and capital expenditures -1.81 billion, giving a free cash flow of 5.09 billion.

Operating Cash Flow	6.90B
Capital Expenditures	-1.81B
Free Cash Flow	5.09B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 49.84%, with operating and profit margins of 22.24% and -5.72%.

Gross Margin	49.84%
Operating Margin	22.24%
Pretax Margin	-3.15%
Profit Margin	-5.72%
EBITDA Margin	28.54%
EBIT Margin	22.24%
FCF Margin	8.16%

Dividends & Yields

Teva Pharmaceutical Industries does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.87%
Shareholder Yield	-0.87%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on June 27, 2004. It was a forward split with a ratio of 2.

Last Split Date	Jun 27, 2004
Split Type	Forward
Split Ratio	2

Scores

Teva Pharmaceutical Industries has an Altman Z-Score of 0.42. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.42
Piotroski F-Score	n/a